GlassScriptPhysician profile
Cheryl R Ward
NPI 1881764595
$5,668.51
in general payments reported to CMS, 2019-2025
41 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $806 · 2022: $1,408 · 2023: $1,836 · 2024: $1,400 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,808 · Travel and Lodging: $582 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,808.16 |
| Travel and Lodging | $581.80 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $935.27 | 2022-2024 | Minimed 780g, Intellis Adaptivestim |
| Lilly USA, LLC | $498.91 | 2021-2024 | Jardiance, Mounjaro, Baqsimi |
| Amgen INC. | $494.77 | 2021-2024 | Krystexxa, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $402.94 | 2022-2024 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $379.81 | 2021-2024 | |
| Corcept Therapeutics | $372.68 | 2022-2024 | Korlym |
| Novo Nordisk INC | $333.96 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $212.26 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $200.28 | 2021-2025 | |
| Vifor Pharma, INC. | $199.15 | 2022-2024 | Veltassa |
| Sanofi-Aventis U.S. LLC | $177.76 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $132.40 | 2021-2024 | Farxiga |
| Renalytix Ai, INC. | $117.01 | 2022-2023 | Kidneyintelx Blood Collection Convenience Kit |
| Insulet Corporation | $114.83 | 2022-2024 | Omnipod |
| Madrigal Pharmaceuticals | $91.19 | 2025 | Rezdiffra |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $89.37 | 2022-2023 | Gattex |
| Cequr Corporation | $86.84 | 2022-2024 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.52 | 2021-2024 | Synjardy, Jardiance, Tradjenta |
| Intra-Sana Laboratories | $68.92 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Janssen Pharmaceuticals, INC | $61.46 | 2021 | |
| Horizon Therapeutics Plc | $55.31 | 2022-2023 | Tepezza |
| Esperion Therapeutics, INC. | $54.16 | 2021 | |
| Ascensia Diabetes Care US INC. | $46.43 | 2023-2024 | |
| Mylan Specialty L.P. | $38.38 | 2021 | |
| Eisai INC. | $37.60 | 2021 | |
| Pfizer INC. | $35.73 | 2023 | |
| Alexion Pharmaceuticals, INC. | $34.86 | 2023-2024 | Ultomiris, Strensiq |
| Amarin Pharma, INC. | $34.22 | 2021 | |
| Aurinia Pharma U.S., INC. | $33.48 | 2022-2024 | Lupkynis |
| Dexcom, INC. | $29.98 | 2022-2023 | Dexcom G6 Transmitter |
| Medicure Pharma INC. | $29.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.39 | 2021 | |
| Verity Pharmaceuticals INC. | $24.33 | 2024 | Tlando |
| Kyowa Kirin, INC. | $23.44 | 2023 | Crysvita |
| Integra Lifesciences Corporation | $22.42 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Tandem Diabetes Care, INC. | $17.06 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Daiichi Sankyo INC. | $16.78 | 2022 | |
| Organogenesis INC. | $16.68 | 2024 | |
| Recordati_rare_diseases_inc. | $16.64 | 2024 | Isturisa, Signifor Lar |
| Ultragenyx Pharmaceutical INC. | $15.18 | 2022 | |
| Antares Pharma, INC. | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.